Discovery of the SARS-CoV-2 Papain-Like Protease Inhibitor MR1-114: From Structure-Based Design to <i>In Vivo</i> Antiviral Efficacy.

J Med Chem · 2026 · PMC13071871 · PMID 41886743

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

While the 100 mg/kg dose showed a trend toward reduction, the 150 mg/kg regimen yielded a statistically significant decrease in lung viral titers compared to the vehicle control.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Discovery of the SARS-CoV-2 Papain-Like Protease Inhibitor MR1-114: From Structure-Based Design to &lt;i&gt;In Vivo&lt;/i&gt; Antiviral Efficacy.

The sentences

Discovery of the SARS-CoV-2 Papain-Like Protease Inhibitor MR1-114: From Structure-Based Design to <i>In Vivo</i> Antiviral Efficacy.